Poly(ethylene glycol) with Observable Shedding

Authors

  • Weiwei Gao Dr.,

    1. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Boston, MA 02115 (USA), Fax: (+1) 617-730-2801
    2. Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139 (USA)
    Search for more papers by this author
  • Robert Langer Dr.,

    1. Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139 (USA)
    Search for more papers by this author
  • Omid C. Farokhzad Dr.

    1. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Boston, MA 02115 (USA), Fax: (+1) 617-730-2801
    Search for more papers by this author

  • We thank Dr. Juliana Chan and Tasha Thomas for the critical review of the manuscript. We are grateful for the assistance from Alla Leshinsky, Natalia Schiller, and Eliza Vasile. This research was supported by National Institutes of Health grants CA119349 and EB003647, and the Koch Prostate Cancer Foundation Award in Nanotherapeutics. Conflict of Interest: O.C.F. and R.L. have financial interest in BIND Biosciences and Selecta Biosciences, biopharmaceutical companies developing therapeutic targeted nanoparticles.

Abstract

original image

Die Spaltung eines Polyethylenglycol(PEG)-Nanopartikel(NP)-Konjugats mit FRET resultiert in einer Fluoreszenz bei 520 nm (siehe Bild). Wurden die Nanopartikel auf Krebszelllinien als Ziel gerichtet, bewirkte die reduzierende Umgebung des Endosoms die Spaltung der Disulfidbindung und das Auflösen der PEG-Schicht.

Ancillary